ERBB2 and breast cancer: To our knowledge, our study is one of the largest multicenter cohort analyses focused on the pCR of HER2-low BC to neoadjuvant chemotherapy, the inconsistency of HER2-low expression between the primary disease and matched residual disease samples, and the biologic and prognostic significance of HER2-low expression in BC patients undergoing neoadjuvant chemotherapy.